RT @TomPMarshall: Sometimes general practices can change practice very dramatically. When statin prescribing guidance changed to high-inten…
RT @TomPMarshall: Sometimes general practices can change practice very dramatically. When statin prescribing guidance changed to high-inten…
RT @TomPMarshall: Sometimes general practices can change practice very dramatically. When statin prescribing guidance changed to high-inten…
RT @TomPMarshall: Sometimes general practices can change practice very dramatically. When statin prescribing guidance changed to high-inten…
Sometimes general practices can change practice very dramatically. When statin prescribing guidance changed to high-intensity, most general practices changed gradually. A few changed dramatically. These would be great case-studies 'how did you do it?' http
RT @BJGPjournal: Statin prescribing: Goldacre et al. discuss the potential for a national strategic approach, given that 2014 NICE guidance…
RT @BJGPjournal: Statin prescribing: Goldacre et al. discuss the potential for a national strategic approach, given that 2014 NICE guidance…
@SABOURETCardio @MichelZedBay Very interesting. This another article exploring appropriate statins use https://t.co/DjzdLisjZ1
RT @openprescribing: Read our paper and use our OpenPrescribing measure to support reviews in your practice, PCN, CCG etc. https://t.co/XQ…
RT @BJGPjournal: Statin prescribing: Goldacre et al. discuss the potential for a national strategic approach, given that 2014 NICE guidance…
RT @BJGPjournal: Statin prescribing: Goldacre et al. discuss the potential for a national strategic approach, given that 2014 NICE guidance…
Read our paper and use our OpenPrescribing measure to support reviews in your practice, PCN, CCG etc. https://t.co/XQQPiB4khM
RT @BJGPjournal: Statin prescribing: Goldacre et al. discuss the potential for a national strategic approach, given that 2014 NICE guidance…
Statin prescribing: Goldacre et al. discuss the potential for a national strategic approach, given that 2014 NICE guidance had minimal impact on suboptimal statin prescribing. LDL = low-density lipoprotein. https://t.co/48Jl85Fn95 https://t.co/jj8UPaNC6O
RT @openprescribing: As always, we have our @bjgp paper on statins https://t.co/6MRVx3mPsm A tool to support review https://t.co/XQQPiB4kh…
RT @openprescribing: @NICEComms recommends that when you prescribe or take a statin, you should (in most cases) select a “high-intensity” s…
RT @openprescribing: Our new @ebmdatalab paper on suboptimal statin treatment regimens is out now in @bjgp. https://t.co/6MRVx3mPsm
RT @openprescribing: Our new @ebmdatalab paper on suboptimal statin treatment regimens is out now in @bjgp. https://t.co/6MRVx3mPsm
As always, we have our @bjgp paper on statins https://t.co/6MRVx3mPsm A tool to support review https://t.co/XQQPiB4khM And a bonus NICE prescribing dashboard https://t.co/qR7kU2jg3j
@NICEComms recommends that when you prescribe or take a statin, you should (in most cases) select a “high-intensity” statin. We found that breaches of NICE guidance on choice of statin remain common, with substantial variation between practices. https:/
Our new @ebmdatalab paper on suboptimal statin treatment regimens is out now in @bjgp. https://t.co/6MRVx3mPsm